
    
      This is a phase I, open-label, dose-escalation study to evaluate the safety, tolerability,
      pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in
      patients with Chronic Spontaneous Urticaria.
    
  